A nationwide population-based cohort study depicted that compared to eosinophilic esophagitis (EoE)-free siblings, there was no higher risk of fractures in EoE patients. Proton pump inhibitors (PPIs) and steroid usage had no effect on the risk of fracture in EoE. Investigators aimed to assess the risk of fractures in EoE people and examined if the most commonly used therapies for EoE were linked with raised fracture risk.

A total of 1263 people having a diagnosis of biopsy-verified EoE for the first fracture of any kind were included in the study. Reference people that were matched by age and gender were obtained from the Total Population Register (n = 5164). Regarding EoE diagnosis, steroid exposure, and PPI use, estimation of hazard ratios (HRs) for fracture was done. Fracture risk was examined between people with EoE and their siblings (n = 1394) in a separate assessment.

In comparison to 234 reference people (12.6/1000 person-years), 69 people with EoE experienced their first-time fracture during the 4521 person-years of follow-up. EoE was not substantially linked to a higher risk of fractures (HR = 1.2) after adjusting for sex, age, country of residence, and birth year. PPI exposure and ingested steroids did not affect fracture risk in EoE patients.

When compared to reference persons who did not have EoE, the risk of fracture was not substantially increased in EoE subjects. Furthermore, the risk of fracture in EoE was not altered by steroid or PPI use.